<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689062</url>
  </required_header>
  <id_info>
    <org_study_id>PROM</org_study_id>
    <nct_id>NCT03689062</nct_id>
  </id_info>
  <brief_title>Premature Rupture of Membranes at 34 to 37 Weeks' Gestation</brief_title>
  <official_title>Premature Rupture of Membranes at 34 to 37 Weeks' Gestation :Active vs Conservative Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prelabour rupture of membrane is deÔ¨Åned as rupture of membranes prior to the onset of labour.
      Approximately 8% of pregnant women at term experience PROM, but the decision as to how term
      PROM should be managed clinically remains controversial, and there is wide variation in
      practice with no clear consensus on what constitutes optimal treatment. Although for the
      majority of women labour will start spontaneously within 24 hours following term PROM, up to
      4%of women will not experience spontaneous onset of labour within seven days.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percentage of patients with chorioamnionitis</measure>
    <time_frame>24 hours</time_frame>
    <description>Clinical chorioamnionitis is defined in the absence of other causes of hyperpyrexia by a temprature of &gt;38 C with either uterine tenderness , leucocytosis , maternal or fetal tachycardia , or foul smelling vaginal discharge</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Premature Rupture of Membrane</condition>
  <arm_group>
    <arm_group_label>conservative group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient assigned to the observation group will be assessed in the labor and delivery suite for 2 to 4 hours with continuous external fetal heart rate monitoring and tocodynamometry. In the absence of non reassuring fetal status , initiation of labor , or infection , these women will be transferred to antepartum room where maternal vital signs. Patients will be restricted to bed rest with bathroom privileges and remained hospitalized until delivary .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to active management will receive induction of labour with intravenous oxytocin with use of controlled infusion pump Oxytocin will be administered by continuous intravenous infusion beginning at 0.5 mU/min , doubling the dose every 30 minutes to 2mU/min , and then increasing by 2 mU/min every 30 minutes there after until a satisfactory labor pattern is achieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>induction of labor</intervention_name>
    <description>oxytocin intravenous drip</description>
    <arm_group_label>active group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>follow up</intervention_name>
    <description>hospitalization and antibiotics</description>
    <arm_group_label>conservative group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm premature rupture of membranes.

          -  Singleton gestation.

          -  Pregnant between 34 weeks 0 days to 36 weeks 6 days.

        Exclusion Criteria:

          -  Non cephalic presentation.

          -  fetal distress.

          -  Labour on admission.

          -  Medical or obstetric complications such as(suspected chorioamnionitis ,hypertensive
             disorders, diabetes mellitus , active genital herpes , placenta previa , infection,
             meconium stained amniotic fluid ,severe fetal anomalies).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>March 22, 2019</last_update_submitted>
  <last_update_submitted_qc>March 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Asmaa Abd El Sattar Ahmed</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

